Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788872 | 1.00 | SLC7A5 (0.56) | SLC7A5GRIA2LTA4HTYRNOS3 | |
| SCHEMBL27525604 | 0.86 | SLC7A5 (0.56) | SLC7A5GRIA2LTA4HNOS3NOS1 | |
| SCHEMBL18481474 | 0.86 | SLC7A5 (0.56) | SLC7A5GRIA2LTA4HNOS3NOS1 | |
| SCHEMBL10561230 | 0.84 | SLC7A5 (0.55) | SLC7A5LTA4HNOS3NOS1NOS2 | |
| SCHEMBL30475895 | 0.84 | SLC7A5 (0.55) | SLC7A5 | |
| SCHEMBL17978075 | 0.84 | SLC7A5 (0.55) | SLC7A5LTA4HNOS3NOS1NOS2 | |
| SCHEMBL27350860 | 0.84 | SLC7A5 (0.55) | SLC7A5LTA4HNOS3NOS1NOS2 | |
| SCHEMBL10561439 | 0.84 | SLC7A5 (0.55) | SLC7A5 | |
| SCHEMBL19664048 | 0.84 | SLC7A5 (0.55) | SLC7A5 | |
| SCHEMBL10560530 | 0.84 | SLC7A5 (0.55) | SLC7A5LTA4HNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | SAIL BIOMEDICINES (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113302176-A | Decarboxylase inhibitors for the treatment of parkinson's disease | 先达生物科技公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10259800-B2 | Method of fluorination using iodonium ylides | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2155663-B1 | SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2017-11-29 | — | — | EP | disclosed |
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-9603832-B2 | Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20150157600-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-20150157602-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-20150157598-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-9051240-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-09 | — | — | US | disclosed |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-31 | — | — | US | disclosed |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-17 | — | — | US | disclosed |
| US-8519000-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-08-27 | — | — | US | disclosed |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | disclosed |
| EP-2155663-A1 | SUBSTITUTED 2- Ý2- (PHENYL) ETHYLAMINO¨ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151702-A1 | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | FLI1, ABL1, PFAS | SLC7A5 642/4885GRIA2 4312/4885LTA4H 2343/4885 |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | SLC7A5 2477/4885GRIA2 104/4885LTA4H 900/4885 |
| US-20150157598-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | SLC7A5 2140/4885GRIA2 114/4885LTA4H 1643/4885 |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | SLC7A5 2513/4885GRIA2 111/4885LTA4H 918/4885 |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | DDC, DDT, DDO | SLC7A5 966/4885GRIA2 1339/4885LTA4H 1572/4885 |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | SLC7A5 2477/4885GRIA2 104/4885LTA4H 900/4885 |
| US-20150157600-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | SLC7A5 2140/4885GRIA2 114/4885LTA4H 1643/4885 |
| US-20150157602-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | SLC7A5 2140/4885GRIA2 114/4885LTA4H 1643/4885 |
| US-10259800-B2 | Method of fluorination using iodonium ylides | FLI1, ABL1, PFAS | SLC7A5 642/4885GRIA2 4312/4885LTA4H 2343/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | SLC7A5 966/4885GRIA2 1339/4885LTA4H 1572/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | SLC7A5 4540/4885GRIA2 1560/4885LTA4H 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.